





NATIONAL CENTER FOR ZOONOTIC, VECTOR-BORNE, AND 
ENTERIC DISEASES (CVH) 
The National Center for Zoonotic, Vector-Borne, and Enteric Diseases (NCZVED) maximizes 
public health and safety nationally and internationally through the elimination, prevention, and 
control of disease, disability, and death caused by suspected and confirmed zoonotic, vector-
borne, foodborne, waterborne, mycotic, prion and related infections.  In carrying out its mission, 
NCZVED: (1) Provides leadership, expertise, and service in laboratory, medical, and 
epidemiological sciences throughout the world; (2) conducts applied research aimed to eliminate, 
prevent, and control disease; (3) translates research findings into public health policies, practices, 
and programs; (4) provides diagnostic and reference laboratory services to relevant partners;  
(5) conducts surveillance and research to determine disease distribution, disease determinants, 
and disease burden nationally and internationally; (6) responds to disease outbreaks domestically 
and abroad; (7) ensures that public health decisions are made objectively and based upon the 
highest quality of scientific data; (8) provides technical expertise, education, and training to 
domestic and international partners; (9) provides leadership to internal and external partners for 
establishing and maintaining screening, treatment, and other elimination, prevention, and control 
programs; (10) develops, implements, and evaluates domestic and international public health 
policies, practices, and programs; (11) communicates information to increase awareness, 
knowledge, and understanding of public health issues domestically and internationally;  
(12) aligns the national center focus with the overall strategic goals of the CDC;  
(13) implements, coordinates, and evaluates programs across CDC, CCID, and NCZVED to 
optimize public health impact; (14) conducts bioterrorism preparedness activities to prevent or 
lessen the severity of bioterrorism incidents; (15) builds strategic partnerships with internal and 
external stake holders; and (16) clarifies the dynamic link between animals, people, and the 
environment to maximize public health impact.  (Approved 3/22/2007) 
Office of the Director (CVH1)
(1) Works with CCID OD to ensure spending plans, budget planning, and budget execution are 
in line with the overall CDC infectious disease strategies and priorities; (2) ensures that the 
CCID strategy is executed by the divisions and aligned with overall CDC goals; (3) co-develops 
execution strategies for the national center with the division directors; (4) provides program and 
science quality oversight; (5) builds leadership at the division and branch levels; (6) evaluates the 
strategies, focus, and prioritization of the division research, program, and budget activities;  
(7) identifies and coordinates synergies between the national center and relevant partners;  
(8) ensures that policy development is consistent and appropriate; (9) facilitates research and 
program activities by providing leadership support; (10) proposes resource priorities throughout 
the budget cycle; (11) ensures scientific quality, ethics, and regulatory compliance; (12) fosters 
an integrated approach to research, program, and policy activities; (13) liaises with HHS and 
partners concerning activities related to vector-borne, zoonotic, and enteric infectious diseases; 
(14) ensures that programmatic goals are achieved with measurable impact; and (15) serves as
primary liaison between NCZVED and the National Center for Health Marketing on 












Division of Parasitic Diseases (CVHB)
The Division of Parasitic Diseases (DPD) prevents and controls parasitic diseases in the U.S. and 
throughout the world by providing diagnostic, consultative, epidemiologic services, and training.  
In carrying out its mission, DPD:  (1) Conducts surveillance, investigations, and studies of 
parasitic diseases to define disease etiology, mode of transmission, and populations at risk, and 
to develop effective methods for diagnosis, prevention, control, and elimination; (2) conducts or 
participates in clinical, field, and laboratory research to develop, evaluate, and improve 
laboratory methodologies, materials and therapeutic practices used for rapid and accurate 
diagnosis and treatment of parasitic diseases; (3) provides epidemic aid, epidemiologic 
consultation, and reference diagnostic services to state and local health departments, other 
federal agencies, and national and international health organizations; (4) conducts a program of 
laboratory and field research in the biology, ecology, and host-parasitic relationships to develop 
better methods for diagnosis, prevention, and control of parasitic diseases; (5) provides scientific 
and technical assistance to other components within CDC when the work requires unique 
expertise or specialized equipment not available in other CDC components; (6) serves as WHO 
Collaborating Centers for Cysticercosis, Research Training and Eradication of Dracunculiasis, 
Control and Elimination of Lymphatic Filariasis, Evaluating and Testing New Insecticides, 
Insecticide Resistance, Insect Vectors; Malaria Control in Africa, Human African 
Trypanosomiasis, Production and Distribution of Malaria Sporozoite ELISAs; (7) maintains 
field-based research and program activities in numerous developing countries; and (8) provides 
marketing/communications support for responsive, evidence-based information targeted to the 
public, local and state health officials, international partners, and private organizations to inform
health decisions, to prevent, and control parasitic diseases in the U.S. and abroad.  (Approved 
3/22/2007) 
Office of the Director (CVHB1)
(1) Works with NCZVED OD to ensure spending plans and budget are in line with the overall 
infectious disease strategies and priorities; (2) ensures that the CCID strategy is executed by the 
divisions and aligned with overall CDC goals; (3) co-develops execution strategies for the 
division with the branch chiefs; (4) provides program and science quality oversight; (5) builds 
leadership at the division and branch levels; (6) evaluates the strategies, focus, and prioritization 
of the division research, program, and budget activities; (7) identifies and coordinates synergies 
between the division and relevant partners; (8) ensures that policy development is consistent and 
appropriate; (9) facilitates research and program activities by providing leadership support;  
(10) proposes resource priorities throughout the budget cycle; (11) ensures scientific quality, 
ethics, and regulatory compliance; (12) fosters an integrated approach to research, program, and 
policy activities; and (13) liaises with HHS and partners as defined in the partnership 
management plan.  (Approved 4/11/07) 
Malaria Branch (CVHBB)
(1) Conducts malaria surveillance, prevention, and control in U.S. residents and visitors by 
monitoring the frequency and distribution of malaria cases that occur in U.S. residents and 




chemotherapy; (2) provides clinical advice and epidemiologic assistance on the treatment, 
control, and prevention of malaria in the U.S. and in malaria endemic countries; (3) provides 
information to the U.S. public and to appropriate agencies and groups on appropriate measures to 
prevent and control malaria; (4) provides consultation, technical assistance, and training to 
malaria-endemic countries and to international and U.S. agencies and organizations on issues of 
malaria prevention and control; (5) conducts epidemiologic, laboratory, and field-based research 
projects, including laboratory and field studies on parasitic diseases to define biology, ecology, 
transmission dynamics, parasite species differences, host-parasite relationships, diagnostics, host 
immune responses, populations at risk, and determinants of morbidity and mortality;  
(6) conducts laboratory studies of malaria parasites utilizing animal models and in vitro systems 
for parasitic relationships, chemotherapy, and vaccine evaluation studies; (7) conducts field 
studies of malaria prevention and control tools and strategies; and (8) conducts assessments of 
malaria monitoring and evaluation methods and program use of these methods.  (Approved 
4/11/2007) 
Parasitic Diseases Branch (CVHBC)
(1) Investigates outbreaks and unusual occurrences of parasitic diseases in concert with states, 
ministries of health, WHO, and other agencies and organizations; (2) conducts surveillance of 
waterborne and foodborne disease outbreaks and other parasitic diseases in the U.S.; (3) provides 
reference and laboratory diagnostic services to physicians and laboratories; (4) transfers 
technologies and expertise in laboratory diagnosis of parasitic infections to public health 
laboratories; (5) provides consultation on the prevention, treatment, and management of parasitic 
diseases to clinicians, laboratorians, departments of health, and other agencies; and provides 
otherwise unavailable anti-parasitic drugs to healthcare providers and ensures compliance with 
FDA’s regulations; (6) provides leadership and technical expertise in support of the agency’s 
bioterrorism preparedness response initiatives and emergency response plans, primarily as they 
relate to waterborne venues; (7) supports the agency’s overall emergency response mandate;  
(8) conducts research on methods to detect parasites and agents of bioterrorism in water, and 
develops emergency public health response plans; (9) conducts field and laboratory 
investigations and research on the etiology, biology, epidemiology, ecology, pathogenesis, 
immunology, genetics, host-parasite relationships, chemotherapy and other aspects of parasitic 
diseases to develop new tools for identifying and controlling parasitic diseases; (10) develops 
and tests new laboratory methods and tools for improved diagnosis, control, and prevention of 
parasitic diseases, and conducts laboratory training courses for public health laboratories;  
(11) carries out and evaluates operational research to evaluate current strategies and develops 
new strategies to support programmatic activities for the control and elimination of parasitic 
diseases, and provides technical assistance to ministries of health, WHO, and other agencies and 
organizations for these programs; (12) provides training to Epidemic Intelligence Service (EIS) 
officers, Emerging Infectious Disease fellows, American Society of Microbiology/NCZVED 
Postdoctoral Fellows, Preventive Medicine Residents, public health prevention specialists, and 
other fellows and students; and (12) prepares and disseminates health communication materials 











(1) Conducts surveillance, field investigations, and laboratory studies on the vectors of parasitic 
diseases of humans, with a focus on malaria, Chagas’ disease, lymphatic filariasis, 
onchocerciasis, and leishmaniasis, with a particular emphasis on the anopheline vectors of 
malaria; (2) serves as WHO Collaborating Centers for pesticides resistance, anopheline vector 
identification, antimalarial drug evaluation, and vector control; (3) develops methods supporting 
the use of pesticides for control of vector-borne diseases, the management of insecticide 
resistance, and the monitoring of anti-parasitic drugs; (4) serves as an international reference 
reagent and anopheline vector repository, providing materials, training, and information related 
to malaria vectors; (5) provides entomological consultation, epidemic aid, and training to local, 
state, federal and foreign agencies and international health organizations on surveillance and 
control of vectors and vector-borne diseases.  (Approved 4/11/2007) 
Division of Vector-borne Infectious Diseases (CVHC)
(1) Conducts surveillance, investigations, and studies of vector-borne viral and bacterial diseases 
to define disease etiology and to develop effective methods and strategies for diagnosis, 
prevention, and control; (2) conducts investigations on the biology, ecology, and control of 
arthropod vectors of viral and bacterial diseases as a basis for development of new and/or 
modification of existing measures for more effective prevention and control; (3) conducts or 
participates in clinical, field, and laboratory studies to develop, evaluate, and improve laboratory 
methods, materials, and therapeutic practices used for diagnosis, prevention, and treatment of 
vector-borne infectious diseases; (4) provides epidemic aid and epidemiologic consultation, upon 
request, to state and local health departments, other federal agencies, and national and 
international health organizations; (5) provides reference/diagnostic services for vector-borne 
viral and bacterial diseases to state and local health departments, other federal agencies, and 
national and international health organizations; (6) conducts research and collaborates on 
development and evaluation of vaccines; (7) provides scientific and technical assistance to other 
CDC components when the work requires unique expertise or specialized equipment not 
available in other components; (8) provides intramural and extramural technical expertise and 
assistance in professional training activities; and (9) serves as designated national and 
international reference centers for vector-borne viral and bacterial diseases.  (Approved 
3/22/2007) 
Office of the Director (CVHC1)
(1) Directs and manages the programs and activities of the Division of Vector-borne Infectious 
Diseases (DVBID); (2) provides leadership and guidance on policy, program planning and 
development, program management, and operations; (3) coordinates or assures coordination with 
the appropriate CDC, CCID, and NCZVED offices on administrative and program matters;  
(4) reviews, prepares, and coordinates congressional testimony and briefing documents related to 
vector-borne infectious diseases, and analyzes programmatic and policy implications of
legislative proposals; (5) represents CDC, CCID, and NCZVED in meetings with other 
governmental, private, and international organizations; (6) serves as CDC, CCID, and 










infectious disease issues; and (7) advises CDC, CCID, and NCZVED on policy matters 
concerning DVBID programs and activities.  (Approved 4/11/2007) 
Arbovirus Diseases Branch (CVHCB)
(1) Conducts surveillance, field investigations and laboratory studies of vector-borne viral agents 
and their vectors; (2) defines disease etiology, ecology, and pathogenesis in order to develop 
methods and strategies for disease diagnosis, surveillance, prevention and control; (3) provides 
diagnostic reference consultation, epidemic aid and epidemiologic consultation to state and local 
health departments, other components of CDC, other federal agencies, and national and 
international health organizations; (4) provides technical expertise and assistance in professional 
training activities to national and international health workers and scientists; and (5) functions as 
a WHO Collaborating Center for Reference and Research on Arboviruses.  (Approved 
4/11/2007) 
Bacterial Diseases Branch (CVHCC)
(1) Conducts national surveillance of plague, tularemia, Lyme disease, and tick-borne relapsing 
fever; (2) conducts multidisciplinary public health-oriented research aimed at developing 
effective disease prevention and control measures for vector-borne bacterial zoonoses;  
(3) provides diagnostic reference consultation, epidemic aid and epidemiologic consultation, 
upon request, to state and local health departments, other components of CDC, other federal 
agencies, and national and international health organizations, and performs relevant duties for the 
Laboratory Response Network; (4) functions as WHO Collaborating Centers for Plague, 
Tularemia, and Borreliosis; (5) investigates disease outbreaks of vector-borne bacterial zoonoses 
in both national and international settings; (6) provides science-based guidance and 
recommendations for prevention and control of vector-borne bacterial zoonoses, in both natural 
and potential terrorism-related outbreaks; (7) provides training on the diagnosis, prevention, and 
investigation of vector-borne diseases; (8) collaborates with universities, industry, and public 
health partners in promoting sound disease prevention policies and practices for vector-borne 
bacterial zoonoses. (Approved 4/11/2007) 
Dengue Branch (CVHCD)
(1) Conducts national and international surveillance, field investigations, and laboratory studies 
of dengue and dengue hemorrhagic fever; (2) provides diagnostic reference consultation, 
epidemic aid and epidemiologic consultation, upon request, to state and local health departments, 
other components of CDC, other federal agencies, and national and international health 
organizations; (3) functions as a WHO Collaborating Center for Reference and Research on 
Dengue Hemorrhagic Fever; (4) provides epidemic aid and investigates dengue epidemics;  
(5) conducts field and laboratory research on the biology, behavior, and control of Aedes aegypti 
and other mosquito vectors of dengue; (6) conducts research and provides consultation and 
assistance to local, state, national, and international health agencies on improved methods for 
surveillance, prevention, and control of epidemic dengue; (7) provides training in laboratory and 







implements, and evaluates new intervention strategies for prevention of epidemic dengue.  
(Approved 4/11/2007) 
Division of Viral and Rickettsial Diseases (CVHD)
The Division of Viral and Rickettsial Diseases (DVRD) maximizes public health and safety 
nationally and internationally through the diagnosis, prevention, and control of disease, 
disability, and death caused by suspected and known zoonotic viral, rickettsial, prion, and related 
infections. In carrying out its mission, DVRD:  (1) Conducts surveillance, investigations, and 
studies of viral and rickettsial diseases, including bioterrorism agents, as well as of transmissible 
spongiform encephalopathies or prion diseases, and severe diseases of unknown, but suspected 
infectious, etiology to define their etiology and epidemiology, and to develop effective methods 
for prevention, diagnosis, treatment, and control; (2) conducts or participates in clinical, field, 
and laboratory research to develop, evaluate, and improve laboratory methods, materials, and 
therapeutic practices used for prevention, diagnosis, treatment, and control of viral, rickettsial, 
and prion diseases, including bioterrorism agents; (3) conducts research on virus transmission to 
develop effective prevention and control strategies and on vaccine effectiveness to assess 
prevention potential; (4) conducts laboratory, clinical, and epidemiologic studies of highly 
hazardous disease agents that require biosafety level 3 or biosafety level 4 security for their safe 
handling; (5) conducts ecological studies to develop and evaluate disease prevention and control 
measures; (6) provides epidemic aid, epidemiologic consultation, reference and diagnostic 
services, and technical assistance to state and local health departments, other federal agencies, 
and national and international health organizations; (7) provides scientific and technical 
assistance to other CDC components when the work requires unique expertise or specialized 
equipment not available in other components; (8) provides routine and specialized laboratory 
training in the diagnosis, isolation, and characterization of viral and rickettsial agents to 
personnel from state and local health departments and other national and international 
organizations; (9) provides training opportunities for EIS officers and others in CDC sponsored 
programs, including postgraduate students, postdoctoral fellows, and other public health and 
laboratory scientists; (10) provides expert pathological support for various infectious diseases to 
other groups at CDC, state and local health departments, other CCID components, and national 
and international organizations; and (11) serves as appropriately designated national and WHO 
Collaborating Centers for viral and rickettsial diseases.  (Approved 3/22/2007) 
Office of the Director (CVHD1)
(1) Directs and manages the programs and activities of  DVRD; (2) provides leadership and 
guidance on policy, program planning and development, program management, and operations; 
(3) coordinates or assures coordination with the appropriate CDC, CCID, and NCZVED offices 
on administrative and program matters; (4) reviews, prepares, and coordinates congressional 
testimony and briefing documents related to viral, rickettsial, and prion diseases, and analyzes 
programmatic and policy implications of legislative proposals; (5) represents CDC, CCID, and 
NCZVED programs and prevention policies in meetings with other governmental, private, and 
international organizations; (6) serves as CDC, CCID, and NCZVED’s primary internal and 
external communications contact regarding viral, rickettsial, and prion disease issues; (7) advises 









(8) conducts or participates in clinical, field, and laboratory research to develop, evaluate, and 
improve laboratory methods, materials, and therapeutic practices used for prevention, diagnosis, 
treatment, and control of prion diseases; (9) coordinates, in collaboration with the appropriate 
CCID and CDC components, international health activities related to the prevention and control 
of prion diseases; (10) conducts or supports surveillance and epidemiologic investigations to 
facilitate the understanding and control of prion diseases and severe diseases of unknown, but 
suspected infectious, etiology; and (11) serves as the primary disseminator of information from
CDC, including clinical and disease prevention consultations to state and local health 
departments and/or federal and international agencies on the illnesses and syndromes caused by 
or related to prions. (Approved 4/11/2007) 
Special Pathogens Branch (CVHDB)
(1) Provides epidemic aid and conducts epidemiologic studies on the detection, prevention, and 
control of highly hazardous viral diseases; (2) provides primary isolation, identification, and 
characterization of highly hazardous disease agents that require biosafety level 3 or biosafety 
level 4 laboratory conditions for their safe handling; (3) develops, evaluates, and improves 
methods for treatment, prevention, and laboratory diagnosis of hazardous disease agents;  
(4) conducts laboratory, clinical, and epidemiologic investigations on the pathogenesis, 
pathophysiology, and prevention of viral infections caused by highly hazardous viruses;  
(5) provides consultation on the clinical and epidemiologic management of suspected cases 
and/or epidemics of these diseases; (6) consults with national and international scientists on the 
design, staffing, and efficient operation of a high hazard pathogen laboratory program; (7) serves 
as a WHO Collaborating Center for Virus Reference and Research for Viral Hemorrhagic 
Fevers; and (8) develops and evaluates health education programs for educating the general 
public and health professionals about infection, treatment, infection control in clinical settings, 
prevention, and laboratory diagnosis of highly hazardous viral diseases.  (Approved 4/11/2007) 
Rickettsial Zoonoses Branch (CVHDC)
(1) Provides epidemic aid, consultation, surveillance, and epidemiologic and/or ecologic 
investigations of rickettsial, and bartonella-associated zoonoses domestically and internationally; 
(2) conducts studies on the microbiology, molecular biology, and pathogenesis of rickettsial, and 
bartonella-associated zoonotic infections; (3) provides reference/diagnostic services domestically 
and internationally; (4) develops, evaluates, and improves methods and reagents for diagnosing 
rickettsial and bartonella-associated diseases; (5) serves as a WHO Collaborating Center for 
Rickettsial and Bartonella-associated Reference and Research; (6) provides consultation and 
laboratory training to state and local health departments and other national and international 
organizations; (7) responds to requests for information regarding rickettsial, and bartonella-
associated zoonotic diseases and their prevention from CDC, health care providers, academic 
institutions, state and local health departments, other government agencies, and the general 
public; (8) collaborates with government agencies, domestic and international academic 
institutions, and the private sector in developing novel diagnostic assays and vaccines for 
rickettsial and bartonella-associated zoonotic diseases; and (9) maintains the Bioterrorism












Poxvirus and Rabies Branch (CVHDD)
(1) Provides epidemic aid, consultation, surveillance, and epidemiologic and/or ecologic 
investigations of poxvirus and rabies associated diseases both domestically and internationally; 
(2) conducts research studies on the microbiology, molecular biology, and pathogenesis of 
poxvirus and rabies infections; (3) provides reference/diagnostic services domestically and 
internationally; (4) develops, evaluates, and improves methods for diagnosing poxvirus and 
rabies associated diseases; (5) serves as one of two WHO Collaborating Centers for Smallpox 
and other Poxvirus Infections and as a WHO Collaborating Center for Reference and Research 
on Rabies; (6) provides consultation and laboratory training to state and local health departments, 
and other national and international organizations; (7) responds to requests for information and 
assistance regarding poxvirus and rabies associated diseases and their prevention, control, and 
treatment from CDC, health care providers, academic institutions, state and local health 
departments, other government agencies, and the general public; (8) collaborates with 
government agencies, domestic and international academic institutions, and the private sector in 
developing novel diagnostic assays and vaccines for poxvirus and rabies associated diseases; and 
(9) maintains the Bioterrorism Laboratory for poxvirus response and research.  (Approved 
4/11/2007) 
Infectious Diseases Pathology Branch (CVHDE)
(1) Provides histopathology, molecular pathology, and ultrastructure reference/diagnostic support 
and epidemic aid to state and local health departments, other federal agencies, and national and 
international health organizations; (2) collaborates with other CDC and non-CDC infectious 
disease laboratories to investigate outbreaks of infectious diseases of unknown etiologies and 
identify new pathogens; (3) develops, improves, evaluates, and applies special 
immunohistologic, ultrastructural, and/or nucleic acid probe technologies for detecting microbial 
agents and/or expressed gene products in tissue specimens or tissue culture; (4) conducts basic 
and applied research into the pathogenesis of infectious diseases; (5) provides intramural and 
extramural technical and professional expertise for assistance in training in infectious disease 
pathology and molecular approaches to the identification of specific nucleic acid sequences and 
special antigens in tissue specimens; and (6) serves as the WHO Collaborating Center for 
Reference Pathology of Hemorrhagic Fevers and other Infectious Diseases.  (Approved 
4/11/2007) 
Chronic Viral Diseases Branch (CVHDG)
(1) Conducts surveillance and hypothesis-driven clinical studies of chronic fatigue syndrome
(CFS); (2) develops novel genomic and proteomic laboratory assays to be used in studies of 
CFS; (3) develops bioinformatics techniques to elucidate the pathophysiology of CFS and similar 
medically unexplained illnesses; (4) develops, executes, and evaluates medical and public 
education programs to decrease morbidity associated with CFS; (5) conducts laboratory-based 
epidemiologic studies of human papillomavirus (HPV) infection and cervical cancer to enable 
effective control and prevention; (6) conducts research concerning human immune responses to 








improves reagents/methods for rapid diagnosis of HPV, CFS, and other related unexplained or 
chronic illnesses; (8) provides epidemiology, molecular biology, bioinformatics, diagnostic 
serology/virology, and immunology consultation and collaboration to national and international 
organizations concerning prevention and control of CFS, cervical cancer, and related chronic or 
medically unexplained illnesses; and (9) provides expert assistance and consultation to national 
and international investigators and organizations regarding sequelae of viral infections.  
(Approved 4/11/2007) 
Division of Foodborne, Bacterial and Mycotic Diseases (CVHE)
The mission of the Division of Foodborne, Bacterial and Mycotic Diseases (DFBMD) is to 
improve public health nationally and internationally through the prevention and control of 
disease, disability, and death caused by zoonotic and enteric bacterial infections and by fungal 
infections. In carrying out its mission, DFBMD: (1) Conducts surveillance, investigations, and 
studies of bacterial, fungal, and actinomycotic diseases to define disease etiology and develop 
effective methods for diagnosis, prevention, and control; (2) conducts or participates in clinical, 
field, and laboratory research to develop, evaluate, and improve laboratory methodologies, 
materials and therapeutic practices used for diagnosis, treatment, investigation, and control of 
bacterial, fungal, and actinomycotic diseases; (3) provides epidemic aid and epidemiological 
consultation, upon request, to state and local health departments, other federal agencies, and 
national and international health organizations; (4) provides reference/diagnostic services for 
bacterial, fungal, and actinomycotic diseases to state and local health departments, other federal 
agencies, and national and international health organizations; (5) provides scientific and 
technical assistance to other CCID components when the work requires unique expertise or 
specialized equipment not available in other components; (6) provides intramural and extramural 
technical expertise and assistance in professional training and proficiency testing activities; and 
(7) serves as appropriately designated national and international reference centers for various 
bacterial, fungal, and actinomycotic diseases and disease groups.  (Approved 3/22/2007) 
Office of the Director (CVHE1)
(1) Directs and manages the programs and activities of DFBMD; (2) provides leadership and 
guidance on policy, program planning and development, program management, and operations; 
(3) coordinates or assures coordination with the appropriate CDC, CCID, and NCZVED offices 
on administrative and program matters; (4) reviews, prepares, and coordinates congressional 
testimony and briefing documents related to foodborne, bacterial, and mycotic diseases, and 
analyzes programmatic and policy implications of legislative proposals; (5) represents CDC, 
CCID, and NCZVED programs and prevention policies in meetings with other components of 
the National Food Safety Initiative (NFSI) and other governmental, private, and international 
organizations; (6) serves as CDC, CCID, and NCZVED’s primary internal and external 
communications contact regarding foodborne disease issues; (7) advises CDC, CCID, and 
NCZVED on policy matters concerning DFBMD  programs and activities; (8) directs activities 
related to the development of long-term CDC, CCID, and NCZVED strategies, policies, and 
budgets for foodborne disease prevention activities conducted as part of the NFSI; (9) allocates 
and tracks NFSI and interagency resources within CDC for foodborne disease surveillance, 









resources for foodborne disease prevention and control activities of state and local health 
departments and other organizations; (11) provides statistical methodology and participates in 
the division’s outbreak investigations and disease reporting systems for ongoing surveillance; 
(12) develops new methods or adapts existing methods for statistical applications in 
epidemiologic or laboratory research studies for the division; (13) provides statistical 
consultation for epidemiologic and laboratory research studies conducted by the division;  
(14) assists researchers with statistical aspects of report writing and prepares statistical portions 
of papers, protocols, and reports written by staff of the division; and (15) trains professional staff 
of the division in statistical methods.  (Approved 4/11/2007) 
Enteric Diseases Epidemiology Branch (CVHEB)
(1) Provides epidemic aid, surveillance, investigation, analysis, and consultation on foodborne 
and waterborne outbreaks of acute gastrointestinal illness to state and local health departments, 
other federal agencies, and national and international health organizations; (2) provides disease
surveillance activities for agents of selected foodborne, waterborne, and other bacterial enteric 
diseases; (3) performs studies to determine risk factors for, and host and etiologic agent factors 
related to, foodborne, waterborne, and other bacterial enteric diseases; (4) coordinates and 
collaborates in national and international enteric disease surveillance, training, and studies, 
including those specifically related to foodborne diseases; (5) coordinates the investigation and 
control of enteric health problems with other CDC groups, and with other U.S. federal and local 
government agencies, state health departments, and foreign health agencies; (6) develops, 
implements, and evaluates prevention strategies for bacterial enteric diseases, especially those 
for persons in resource-poor settings and for vulnerable populations; (7) develops and 
implements prevention strategies for foodborne and waterborne diseases in consultation with 
regulatory agencies, the food industry, and other health agencies; (8) conducts surveillance for 
and analysis of antimicrobial resistance in enteric organisms; (9) provides training to EIS 
officers, fellows, students, and visiting scientists from the U.S. and abroad; (10) prepares and 
disseminates health communication materials on the prevention and treatment of acute bacterial 
enteric diseases; and (11) provides information and expert advice to policy-makers about acute 
enteric diseases. (Approved 4/11/2007) 
Enteric Diseases Laboratory Branch (CVHED)
1) Provides expert identification and laboratory-based disease surveillance activities for agents of
foodborne and diarrheal diseases; (2) supports enteric pathogen identification and 
characterization at the state, federal, and international levels through reference identification, 
consultation, and training; (3) develops, validates and implements new or improved methods for 
enteric pathogen identification and characterization; (4) maintains expertise in microbiology, 
molecular biology, immunology and microbial pathogenesis of organisms that cause foodborne 
and diarrheal diseases; (5) provides expert identification, laboratory-based disease surveillance, 
and outbreak investigation activities for agents of botulism; (6) provides expertise in developing 
and validating new methods to enhance U.S. laboratory capacity for preparedness and response 
to bioterrorism events involving Botulinum toxins.  (7) conducts laboratory surveillance, and 
provides epidemic aid and consultation on the investigation of foodborne and diarrheal diseases 











implements enteric pathogen subtyping methods for cluster identification and for facilitating the 
identification of sources of foodborne and diarrheal disease outbreaks; (9) establishes and 
maintains libraries of DNA ‘fingerprints’ of enteric pathogens to facilitate early recognition and 
investigation of foodborne disease outbreaks; (10) coordinates, collaborates, and provides 
expertise in regional, national and international surveillance studies of foodborne and diarrheal 
disease including microbial source tracking and attribution of foodborne illnesses to specific  
food types. (Approved 10/09/2008) 
Bacterial Zoonoses Branch (CVHEE)
(1) Provides assistance in control of endemic and epidemics disease, and exploits opportunities 
to improve control and prevention of bacterial zoonotic diseases and mycobacterium infections 
other than tuberculosis; (2) provides subject matter expertise for preparedness and emergency 
response for anthrax, brucellosis, melioidosis, and glanders; (3) provides reference and 
diagnostic activities for agents causing these diseases and for the identification of unknown 
bacterial isolates associated with human diseases; (4) conducts laboratory research for improved 
laboratory identification and subtyping of bacterial zoonoses and identification of novel bacterial 
pathogens; (5) develops, implements, and evaluates domestic and international prevention 
strategies for these diseases; (6) maintains WHO Collaborating Centers for epidemiology and 
laboratory research of bacterial zoonotic diseases; and (7) collaborates with other CDC NCs, 
NCZVED divisions, state and federal agencies, Ministers of Health, WHO, PAHO, private 
partners and other governmental organizations involved in public health.  (Approved 4/11/2007) 
Mycotic Diseases Branch (CVHEG)
(1) Conducts laboratory studies and provides epidemic aid, surveillance, and consultation on the 
control of emerging, reemerging, and opportunistic mycotic diseases; (2) provides reference and 
diagnostic activities for agents causing these diseases and for the identification of unknown 
mycotic isolates associated with human disease; (3) coordinates and collaborates in national and 
international studies and surveillance for mycotic diseases; (4) develops and evaluates methods 
for the diagnosis of emerging, reemerging, and opportunistic mycotic diseases; (5) develops, 
implements, and evaluates prevention strategies for these diseases; and (6) collaborates with 
other CDC NCs, NCZVED divisions, state and federal agencies in addressing reemerging 
mycotic diseases. (Approved 4/11/2007) 
Office of Critical Information Integration and Exchange (CVHG)
The mission of the Office of Critical Information Integration and Exchange (OCIIX) is to 
provide a CDC-wide resource that facilitates the exchange, integration, and visualization of 
relevant information from a variety of sources to enhance Agency and programmatic situational 
awareness for decision making and early event detection.  To carry out its mission, OCIIX:   
(1) Develops tools that enable social networking and the creation of communities of practice to 
facilitate the exchange of information essential to developing an accurate and complete picture of 
developments that could threaten health worldwide; (2) identifies and/or develops information 
technologies to improve access to the integrated information; (3) detects, analyzes and 







services that reduce emergency response times for the CDC Office of the Director and Agency 
programs; and (4) analyzes, integrates and provides information to key stakeholders to widen 
their understanding of emerging threats and to enhance the effectiveness of subsequent response 
strategies. (Approved 5/8/2008)
